218 related articles for article (PubMed ID: 15842347)
21. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.
Godier A; Mazoyer E; Cymbalista F; Cupa M; Samama CM
J Thromb Haemost; 2007 Feb; 5(2):244-9. PubMed ID: 17129221
[TBL] [Abstract][Full Text] [Related]
22. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
23. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
24. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
Guzzetta NA; Russell IA; Williams GD
Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
[TBL] [Abstract][Full Text] [Related]
25. Recombinant activated coagulation factor VII and bleeding trauma patients.
Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
[TBL] [Abstract][Full Text] [Related]
26. The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.
McMullin NR; Kauvar DS; Currier HM; Baskin TW; Pusateri AE; Holcomb JB
Curr Surg; 2006; 63(4):246-51. PubMed ID: 16843774
[TBL] [Abstract][Full Text] [Related]
27. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
Karkouti K; Arellano R; Aye T; Dupuis JY; Kent B; Lee TW; Lin Y; Ralley F; MacAdams C; Mazer CD; Muirhead B; Rheault MR; Rochon A; Syed S; Waters T; Wong B
Can J Anaesth; 2014 Aug; 61(8):727-35. PubMed ID: 24890696
[TBL] [Abstract][Full Text] [Related]
28. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
29. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
[TBL] [Abstract][Full Text] [Related]
30. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage.
Ahonen J; Jokela R; Korttila K
Acta Anaesthesiol Scand; 2007 Aug; 51(7):929-36. PubMed ID: 17488316
[TBL] [Abstract][Full Text] [Related]
31. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
32. Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety.
Squizzato A; Ageno W
Curr Drug Saf; 2007 May; 2(2):155-61. PubMed ID: 18690962
[TBL] [Abstract][Full Text] [Related]
33. "Off-license" use of recombinant activated factor VII.
Ghorashian S; Hunt BJ
Blood Rev; 2004 Dec; 18(4):245-59. PubMed ID: 15501553
[TBL] [Abstract][Full Text] [Related]
34. Recombinant activated factor VII in cardiac surgery: a systematic review.
Warren O; Mandal K; Hadjianastassiou V; Knowlton L; Panesar S; John K; Darzi A; Athanasiou T
Ann Thorac Surg; 2007 Feb; 83(2):707-14. PubMed ID: 17258029
[TBL] [Abstract][Full Text] [Related]
35. The potential use of recombinant activated factor VII in trauma and surgery.
Sapsford W
Scand J Surg; 2004; 93(1):17-23. PubMed ID: 15116814
[TBL] [Abstract][Full Text] [Related]
36. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII.
Tawfick WA; Tawfik S; Hynes N; Mahendran B; Sultan S
Vascular; 2006; 14(1):32-7. PubMed ID: 16849021
[TBL] [Abstract][Full Text] [Related]
37. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
38. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
[TBL] [Abstract][Full Text] [Related]
39. Recombinant activated factor VII for the treatment of life-threatening haemorrhage.
Eikelboom JW; Bird R; Blythe D; Coyle L; Gan E; Harvey M; Isbister J; Leahy M; McIlroy D; Rahimpanah F; Ramanthan S; Strasser S; Ward C; Watts A; Towler S; Yi Q
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):713-7. PubMed ID: 14614349
[TBL] [Abstract][Full Text] [Related]
40. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
